Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03366103 · ClinicalTrials.gov registry record · Phase 1
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03366103: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03366103 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03366103, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vistusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving navitoclax and vistusertib may work better than navitoclax alone in treating patients with small cell lung cancer and solid tumors.
Interventions
- BIOLOGICAL Navitoclax
- DRUG Vistusertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2022-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03366103
The ClinicalTrials.gov registry entry for NCT03366103 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Navitoclax is the first listed.
NCT03366103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03366103 about?
NCT03366103 is a clinical study titled "Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors". This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different wa...
What is the current status of trial NCT03366103?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-03-20. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT03366103?
The interventions under investigation include: Navitoclax (BIOLOGICAL), Vistusertib (DRUG).
Who is sponsoring clinical trial NCT03366103?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.